We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Consider progressive multifocal encephalopathy (PML) in the differential diagnosis for patients with new or worsening neurological signs or symptoms, even several years after treatment with cladribine.
Over-correction of haemoglobin concentration may increase the risk of death and serious cardiovascular events in patients with chronic kidney disease; it may increase the risk of thrombosis and related complications in patients with cancer.
Stop prescribing Picato and consider other treatment options for actinic keratosis as appropriate. The licence of ingenol mebutate (Picato) has been suspended as a precautionary measure while the European Medicines Agency (EMA) continues to investigate concerns about a possible increased...
A major new cutting edge radiotherapy treatment will be available in the UK thanks to £250 million of government funding.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
The new treatment aid will allow surgeons to identify areas of the brain affected by cancer more accurately, helping up to 2,000 patients a year.
First published during the 2016 to 2019 May Conservative government
New safety information for intensive monitoring of Erlotinib.
TCR2 Therapeutics will become the first international organisation to work with the Cell and Gene Therapy Catapult manufacturing centre.
(All types, makes and models) Report cases in women who have breast implants or who have had them removed. (MDA/2014/027)
SIN Spain organised a workshop between Cancer Research UK and the Spanish National Oncology Research Centre on 13th October 2014
(Hospira UK Limited) Paclitaxel 6mg/ml concentrate for solution for infusion; 100mg in 16.7ml - risk of the exterior of vials contaminated with Methotrexate (EL (16)A/05)
Patients with existing meningioma or a history of meningioma must not be prescribed high-dose (≥25 mg per day) cyproterone acetate.
Updated information about relevant policy and implementation news for the National Cancer Programme.
The ANNOUNCE study failed to show clinical efficacy for olaratumab in its current indication of advanced soft tissue sarcoma and the benefit risk balance is therefore now considered negative. No new patients should be started on olaratumab therapy.
A letter detailing arrangements for the interim cancer drug fund announced on 27th July. Download Interim cancer drugs funding, letter from…
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be measured before starting treatment with tocilizumab and monitored every 4–8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter. Serious liver injury has been reported...
OFT closed case: Anticipated acquisition by UCB SA of Celltech Group plc.
Five cases of necrotising fasciitis have been reported in patients treated with panitumumab in combination with chemotherapy.
Rare cases of atypical femoral fracture with long-term use.
Baroness Randerson visits £30m Hadyn Ellis Building to see groundbreaking research into cancer and mental illness
National Cancer Programme bulletin, issue 22, October 2011.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).